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Articles
Cediranib in patients with alveolar soft-part sarcoma 
(CASPS): a double-blind, placebo-controlled, randomised, 
phase 2 trial
Ian Judson, James P Morden*, Lucy Kilburn, Michael Leahy, Charlotte Benson, Vivek Bhadri, Quentin Campbell-Hewson, Ricardo Cubedo, 
Adam Dangoor, Lisa Fox, Ivo Hennig, Katy Jarman, Warren Joubert, Sarah Kernaghan, Antonio López Pousa, Catriona McNeil, Beatrice Seddon, 
Claire Snowdon, Martin Tattersall, Christy Toms, Javier Martinez Trufero, Judith M Bliss
Summary
Background Alveolar soft-part sarcoma (ASPS) is a rare soft-tissue sarcoma that is unresponsive to chemotherapy. 
Cediranib, a tyrosine-kinase inhibitor, has shown substantial activity in ASPS in non-randomised studies. 
The Cediranib in Alveolar Soft Part Sarcoma (CASPS) study was designed to discriminate the effect of cediranib from 
the intrinsically indolent nature of ASPS.
Methods In this double-blind, placebo-controlled, randomised, phase 2 trial, we recruited participants from 
12 hospitals in the UK (n=7), Spain (n=3), and Australia (n=2). Patients were eligible if they were aged 16 years or 
older; metastatic ASPS that had progressed in the previous 6 months; had an ECOG performance status of 0–1; life 
expectancy of more than 12 weeks; and adequate bone marrow, hepatic, and renal function. Participants had to have 
no anti-cancer treatment within 4 weeks before trial entry, with exception of palliative radiotherapy. Participants were 
randomly assigned (2:1), with allocation by use of computer-generated random permuted blocks of six, to either 
cediranib (30 mg orally, once daily) or matching placebo tablets for 24 weeks. Treatment was supplied in number-
coded bottles, masking participants and clinicians to assignment. Participants were unblinded at week 24 or sooner if 
they had progression defined by Response Evaluation Criteria in Solid Tumors (version 1.1); those on placebo crossed 
over to cediranib and all participants continued on treatment until progression or death. The primary endpoint was 
percentage change in sum of target marker lesion diameters between baseline and week 24 or progression if sooner, 
assessed in the evaluable population (all randomly assigned participants who had a scan at week 24 [or sooner if they 
progressed] with target marker lesions measured). Safety was assessed in all participants who received at least one 
dose of study drug. This study is registered with ClinicalTrials.gov, number NCT01337401; the European Clinical 
Trials database, number EudraCT2010-021163-33; and the ISRCTN registry, number ISRCTN63733470 recruitment is 
complete and follow-up is ongoing.
Findings Between July 15, 2011, and July 29, 2016, of 48 participants recruited, all were randomly assigned to cediranib 
(n=32) or placebo (n=16). 23 (48%) were female and the median age was 31 years (IQR 27–45). Median follow-up was 
34·3 months (IQR 23·7–55·6) at the time of data cutoff for these analyses (April 11, 2018). Four participants in the 
cediranib group were not evaluable for the primary endpoint (one did not start treatment, and three did not have their 
scan at 24 weeks). Median percentage change in sum of target marker lesion diameters for the evaluable population 
was −8·3% (IQR −26·5 to 5·9) with cediranib versus 13·4% (IQR 1·1 to 21·3) with placebo (one-sided p=0·0010). The 
most common grade 3 adverse events on (blinded) cediranib were hypertension (six [19%] of 31) and diarrhoea 
(two [6%]). 15 serious adverse reactions in 12 patients were reported; 12 of these reactions occurred on open-label 
cediranib, and the most common symptoms were dehydration (n=2), vomiting (n=2), and proteinuria (n=2). 
One probable treatment-related death (intracranial haemorrhage) occurred 41 days after starting open-label cediranib 
in a patient who was assigned to placebo in the masked phase.
Interpretation Given the high incidence of metastatic disease and poor long-term prognosis of ASPS, together with 
the lack of efficacy of conventional chemotherapy, our finding of significant clinical activity with cediranib in this 
disease is an important step towards the goal of long-term disease control for these young patients. Future clinical 
trials in ASPS are also likely to involve immune checkpoint inhibitors.
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Introduction
Alveolar soft-part sarcoma (ASPS) is rare, accounting for 
less than 0·5% of all soft-tissue sarcomas. It predominantly 
affects young people, with a median age at presentation of 
25 years and most patients younger than 30 years at 
diagnosis.1 ASPS commonly involves the lower limb, with 
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a slight predominance in women and a high incidence of 
metastatic disease at diagnosis.1 Although metastases are 
intrinsically indolent, the long-term outlook is poor.2 
Lieberman and colleagues2 report that only 15% of patients 
with no metastases at diagnosis remained metastasis free 
after 20 years of follow-up, with a median metastasis-free 
period of 6 years and median survival after development 
of metastases of 2 years. If patients presented with 
metastases, median survival was 3 years, compared with 
11 years for patients who were metastasis free at diagnosis, 
and survival tended to worsen with increasing age.2 
Unusually for a soft-tissue sarcoma, in addition to lung 
metastases, ASPS also metastasises to brain and bone.3 
Histologically, the disease is characterised by uniform 
polygonal cells arranged in a pseudoalveolar pattern 
separated by vascular septae, and molecular studies4 have 
shown a characteristic non-reciprocal translocation, t(X;17)
(p11·2;q25), resulting in the ASPSCR1–TFE3 fusion gene 
that replaces the N-terminal portion of TFE3 in a manner 
consistent with transcriptional deregulation.4
ASPS cells have periodic acid-Schiff (PAS)-positive 
precrystalline granules that contain monocarboxylate 
transporter 1 (MCT1) and its chaperone basigin (CD147).5 
In a genetically engineered mouse study6 that used the 
ASPSCR1–TFE3 gene to drive oncogenesis, the mice 
developed tumours in the brain and orbit—ie, the cranial 
vault—a region known to have the highest lactate 
concentrations in the mouse. Metabolic studies6 showed 
that ASPS cells in this model used lactate as an energy 
source. Lactate is imported via MCT1 and is converted 
directly to pyruvate for entry into the citric acid cycle. In 
addition to supplying energy, lactate acts to stimulate cell 
proliferation and angiogenesis because of the excess 
pyruvate, which upregulates hypoxia-inducible factor 1-α 
(HIF1-α) via inhibition of the prolyl hydroxylase 
responsible for its degradation,7 raising the possibility 
that the lactate transporter MCT1 could be a therapeutic 
target for inhibition of tumour angiogenesis.8
Cediranib is a receptor tyrosine-kinase inhibitor, the 
targets of which include the VEGF receptors VEGFR1, 
VEGFR2, and VEGFR3; KIT; and platelet-derived growth 
factor receptors. After observation of a prolonged partial 
remission with cediranib in a patient with locally 
advanced and metastatic ASPS treated in a phase 2, 
hypertension management study (NCT00264004),9 an 
opportunity arose to treat a further six patients with 
ASPS who were treated in a cediranib pharmacodynamic 
study of patients with soft-tissue sarcoma, most of whom 
had gastrointestinal stromal tumours (D8480C00046).10 
Strong evidence of the clinical activity of cediranib 
against ASPS, in terms of durable partial remissions and 
disease stabilisation, led to further studies including a 
single-arm, phase 2 trial of cediranib in ASPS by the US 
National Cancer Institute.11
Other tyrosine-kinase inhibitors have also been shown 
to have activity in ASPS. A direct antitumour effect has 
been shown with sunitinib mediated by platelet-derived 
growth factor receptor β (PDGFRB), VEGFR2, and RET, 
with five partial responses in nine patients and median 
progression-free survival on treatment of 17 months 
(range 2–33).12 In adults, a retrospective study reported 
one complete response and seven partial responses in 
30 patients treated with pazopanib, with a median 
progression-free survival of 13·6 months (range 1·6–32·2) 
and only little activity with trabectedin.13 In 40 patients 
with ASPS and a rearrangement of the TFE3 gene treated 
with the serine/threonine-protein kinase Haspin 
homolog ALK1 and hepatocyte growth factor receptor 
Research in context
Evidence before this study
Before undertaking this study, the available data concerning 
the activity of the experimental drug cediranib (previously 
AZD2171) in the treatment of alveolar soft part sarcoma 
(ASPS) consisted of an index case of extended response in 
ASPS in a phase 2 trial, a phase 2 study of cediranib in the 
treatment of gastrointestinal stromal tumours and soft 
tissue sarcomas including ASPS, and a phase 2 single-arm 
study, which was ongoing at the time the CASPS trial was 
being developed and has since shown activity in ASPS. 
Other studies involving ASPS, ongoing and completed, 
were identified using the ClinicalTrials.gov website, searching 
for “alveolar soft part sarcoma”; PubMed, searching for 
publications in English between Jan 1, 2000, and 
Dec 31, 2018, using the search terms “tyrosine kinase 
inhibitor”, “anti-angiogenic agent”, and “alveolar soft part 
sarcoma”; via presentations at international meetings, 
and personal communications. Other drugs with reported 
activity in ASPS include sunitinib, pazopanib, and anlotinib.
Added value of this study
ASPS has a high metastatic potential, but usually slow disease 
progression, and sometimes spontaneous disease arrest and 
even, rarely, regression can occur. These characteristics make 
progression-free survival an unreliable endpoint for this disease. 
By undertaking a placebo-controlled randomised trial with 
tumour size as the primary endpoint, we ensured that the activity 
of cediranib could be measured reliably. To our knowledge, this 
study is the only randomised trial to be reported in ASPS so far.
Implications of all the available evidence
Although the precise molecular targets of cediranib in ASPS are 
not known, this study has confirmed the value of this drug in the 
treatment of advanced ASPS. The relative importance of 
angiogenesis inhibition and immunomodulation are the subject 
of active investigation and translational research from this study 
will be published in due course. Confirmation of the activity of 
cediranib in a randomised, placebo-controlled trial will provide a 
sound basis for future research with this and other drugs for ASPS.
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(MET) inhibitor crizotinib, one patient had a partial 
response and 35 had stable disease as their best response, 
with 1-year progression-free survival of 37·5% (95% CI 
22·9–52·1).14 Anlotinib has also been reported to have 
activity in a prospective basket study15 in which six of 
13 patients with ASPS had partial responses and the 
median progression-free survival was 21 months. 
Pazopanib is the only multi-targeted tyrosine-kinase 
inhibitor approved for second-line or further-line treat-
ment of all soft-tissue sarcomas. Preliminary reports of 
activity with immunomodulatory drugs have been 
presented in the past 2 years.15,16
The Cediranib in Alveolar Soft Part Sarcoma (CASPS) 
trial aimed to assess the efficacy of cediranib in the 
treatment of ASPS. The double-blind, placebo-controlled 
design was chosen because of the unusual biology of this 
cancer, which, although having strong metastatic 
potential, is characterised by indolent metastatic tumour 
growth and periods of spontaneous stabilisation, making 
single-group uncontrolled studies difficult to interpret.3,12 
Ethical challenges exist in placebo groups, which we 
mitigated by having a 2:1 randomisation favouring 
active treatment, restricting the no-treatment period to 
24 weeks, and allowing crossover to active treatment on 
disease progression or, if no progression, after week 24. 
At entry, patients were required to have progressed in the 
previous 6 months, hence 6 months was chosen as the 
period for comparison between cediranib and placebo. 
A preliminary report of CASPS was presented at the 2017 
Annual General Meeting of the American Society of 
Clinical Oncology.17
Methods
Study design and participants
In this multicentre, double-blind, placebo-controlled, 
randomised, phase 2 trial, participants were recruited 
from 12 hospitals in the UK (n=7), Spain (n=3), Australia 
(n=2). Eligible patients were women or men aged 16 years 
or older, with a histologically confirmed diagnosis of 
ASPS. A tumour block was required for central review 
and confirmation of the presence of t(X;17)(p11·2:q25) 
translocation. Patients were required to have measurable 
metastatic disease that had progressed according to the 
Response Evaluation Criteria in Solid Tumors (RECIST) 
version 1.1 in the previous 6 months; an ECOG perfor-
mance status of 0–1; life expectancy of more than 
12 weeks; and adequate bone marrow, hepatic, and renal 
function (absolute neutrophil count >1·5 × 10⁹ per L; 
platelet count >100×10⁹ per L; serum bilirubin 
<1·5 × upper limit of normal [ULN], unless proven 
Gilbert’s syndrome; alanine transaminase or aspartate 
transaminase <2·5 × ULN or <5 × ULN if liver metastases 
present; serum creatinine <1·5 × ULN or creatinine 
clearance >50 mL per min). The restrictive criterion of 
progression in the previous 6 months was based on the 
known indolent nature of the disease. CASPS thus 
differs from other ASPS studies that do not have such 
restricted eligibility criteria. Patients with brain 
metastases were eligible if their disease was controlled 
with a stable dose of corticosteroid or a non-enzyme-
inducing anticon vulsant. Exclusion criteria included 
history of gastro intestinal disorder likely to impair 
absorption of cediranib; poorly controlled hypertension; 
any severe or uncon trolled comorbidity—eg, active 
infection; prolonged QT interval—ie, QTc ≥480 msec 
(using Bazetts correction) or family history of long QT 
syndrome; substantial recent haemorrhage (>30 mL 
bleeding or episode in previous 3 months); major 
thoracic or abdominal surgery in previous 14 days; recent 
history of thrombosis; pregnant or breastfeeding women; 
unwillingness to use adequate birth control measures; 
anticancer treatment in the previous 4 weeks, with 
the exception of palliative radiotherapy; known hyper-
sensitivity to any excipient of cediranib; history of other 
malignancy except cancer in situ unless individual had 
been disease free for more than 2 years and with tissue 
diagnosis of ASPS from target lesion; and any other 
concomitant anticancer therapy except steroids. A full list 
of exclusion criteria is in the appendix (pp 27–28). 
Previous treatment with cediranib was added as an 
exclusion criterion and approved as a protocol 
amendment on the advice of the joint Independent 
Data Monitoring and Steering Committee (IDMSC) on 
Sept 24, 2014.
Patients provided written, informed consent before 
enrolment. The study protocol is in the appendix 
(pp 9–75). The study was approved by the South West 
London Research Ethics Committee 4 (REC reference 
10/H0806/118) in the UK; the Clinical Research Ethics 
Committee of Hospital de la Santa Creu i Sant Pau, 
Barcelona (12/070 [R]), in Spain; and by the Metro 
South Health Service District Human Research Ethics 
Committee, QLD (HREC/12/QPAH/10), and the Sydney 
Local Health District Human Research Ethics Committee 
(HREC/12/RPAH/26), in Australia. The Clinical Trials 
and Statistics Unit at The Institute of Cancer Research, 
London, UK (ICR-CTSU), had overall responsibility for 
trial coordination with two international trials groups 
(Grupo Español de Investigación en Sarcomas [GEIS], 
Madrid, Spain, and Australasian Sarcoma Study Group 
[ASSG], Melbourne, Australia) having responsibility for 
regulatory and ethics submissions, monitoring, and 
safety reporting within their respective countries. Safety 
and efficacy data were reviewed regularly by the IDMSC. 
A Trial Management Group was responsible for the day-
to-day running of the trial. The ICR-CTSU undertook all 
central statistical monitoring, interim, and final analyses.
Randomisation and masking
Participants were randomly allocated (2:1) to cediranib or 
placebo by computer-generated random permuted block 
method (block size of six) derived by ICR-CTSU, and the 
random isation sequence centrally was generated 
centrally at the ICR-CTSU. Because of the small trial 
See Online for appendix
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size, we did not use any stratification factors. Both the 
participants and clinicians were masked to treatment 
allocation until week 24 or until disease progression if 
this occurred sooner.Treatment was supplied in number-
coded bottles, masking participants and clinicians to 
assignment.
Procedures
Depending on treatment allocation, participants 
received cediranib or matching placebo 30 mg orally 
once daily, for the first 24 weeks of the study. At 
24 weeks, or sooner if the patient had confirmed disease 
progression according to RECIST, participants were 
unmasked. Participants allocated to placebo crossed 
over to open-label cediranib and continued on treatment 
until disease progression or death. Participants 
allocated to cediranib who had not progressed by 
24 weeks continued on cediranib until progression or 
death. Participants could withdraw from the trial at any 
point and for any reason.
Clinical assessments, including physical examination, 
symptom review, and routine blood and urine 
investigations, took place at 2 and 4 weeks, then once 
every 4 weeks until week 24, every 8 weeks up to 48 weeks, 
then every 12 weeks until progression or treatment 
discontin uation. Assessments for participants crossing 
over from placebo to cediranib were recommenced 
similarly to in the first 24 weeks for the original cediranib 
group. Tumour assessments (CT or MRI if indicated) 
were done at baseline, every 8 weeks until week 48, and 
then every 12 weeks until disease progression or death. 
Blood pressure was monitored at least weekly for the first 
4 weeks, then monthly up to 24 weeks and thereafter as 
specified in the protocol—ie, every 8 weeks up to 
48 weeks and every 12 weeks thereafter. Masked radiology 
review was not planned as part of this study, although 
translational imaging studies are planned.
Toxicity was assessed using National Cancer Institute 
Common Terminology Criteria for Adverse Events 
(CTCAE) version 4 on the same schedule as the clinical 
assessments. Coding was done by use of the Medical 
Dictionary for Regulatory Activities (version 14).
Treatment-related toxicities of grade 3 or worse, or 
repeated episodes of grade 2 toxicities not responding to 
adequate supportive measures were managed initially 
with dose interruptions of 2–5 days, with reintroduction 
on resolution at the same dose. Longer interruptions 
up to 14 days were permitted for chronic problems 
such as nausea, diarrhoea, and palmar-plantar erythro-
dysaesthesia syndrome if refractory to supportive 
treatment—eg, antiemetics or loperamide. If toxic effects 
continued, a dose reduction to 20 mg daily was per-
mitted. Treatment with cediranib was to be discontinued 
permanently for gastrointestinal perforation, wound 
dehiscence, severe haemorrhage, or severe uncontrolled 
hypertension. Abnormal thyroid function was treated 
with L-thyronine as appropriate.
Outcomes
The primary endpoint was percentage change in the sum 
of the longest diameters (or shortest if nodal disease) of 
target marker lesions, measured at 24 weeks (or at 
progression if sooner) from the date of treatment 
assignment. Protocol-defined secondary endpoints were 
the proportion of participants with an objective response 
at week 24, defined as the proportion of participants 
having either a partial or complete response at the end of 
blinded treatment; best response up to week 24, defined as 
best response at any point during blinded treatment; best 
percentage reduction of target marker lesion size during 
blinded treatment; progression-free survival defined as 
time from random assignment to disease progression 
(defined by RECIST version 1.1) or death from any cause; 
the proportion of patients alive and progression free at 
12 months; overall survival, defined as time from random 
assignment to death (any cause); and the safety and 
tolerability profile of cediranib in all participants. For 
progression free survival, participants who were alive and 
progression-free were censored at the date of last known 
follow-up. Participants with non-RECIST confirmed 
progression (eg, radio logically confirmed but lesions not 
measured according to RECIST, or participants with 
clinical evidence of progression only) were censored at the 
date of their progression.
Exploratory endpoints included radiological responses 
using Choi criteria, identification of predictive angio-
genesis markers of response, to describe changes in 
angiogenesis markers and expression of angiogenesis 
regulatory genes in peripheral blood and optional tumour 
biopsies, and to explore changes in circulating endothelial 
cells and other rare cells events, including potential 
sarcoma circulating cells. These exploratory endpoints 
will be reported elsewhere once these data are available.
Statistical analysis
Our study size was informed by previous studies of 
participants with metastatic ASPS. In the previously 
mentioned cediranib pharmacodynamic phase 2 study 
(D8480C00046),10 of 36 participants (ten of whom had 
soft-tissue sarcoma and 26 had a gastrointestinal stromal 
tumour), six participants with metastatic ASPS had a 
mean decrease in tumour size at 8 weeks of 25%, with a 
coefficient of variation of 19%. The second scan at 
16 weeks showed that four of six participants had a more 
than 30% decrease in tumour size—ie, a partial response. 
We assumed that a smaller effect and greater coefficient 
of variation than these results might be observed in a 
larger trial; therefore, we determined that 36 participants 
would be required to detect a 20% decrease in the sum of 
the diameters of target marker lesions at 24 weeks 
between placebo and cediranib with a coefficient of 
variation of 25%, 80% power, and a one-sided significance 
level of 5%. We calculated this sample size for a two-
sample t test of the log transformation of the sum of the 
diameters of target marker lesions using the sampsi 
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command in Stata. We did a formal interim analysis after 
18 participants (12 assigned to cediranib and six assigned 
to placebo) had 24 weeks of follow-up data (or had disease 
progression if sooner) to determine early activity of 
cediranib. Recruitment to the study was not halted while 
the interim analysis was undertaken.
We used descriptive statistics to show the baseline 
demographic information of the participants who were 
enrolled. We compared the primary endpoint between 
cediranib and placebo groups using the Wilcoxon-Mann-
Whitney test. We chose to present the data as medians 
and IQRs and to use non-parametric tests a priori 
because of the uncertainty around whether or not the 
data would be normally distributed. We used waterfall 
plots to graphically present the primary endpoint result. 
The principal analysis population for the primary 
endpoint was the evaluable population, defined as all 
randomly assigned participants (the intention-to-treat 
[ITT] population) who had a scan at week 24 (or a scan at 
progression if earlier) with target marker lesions 
measured. We did a sensitivity analysis of the primary 
endpoint and of the best percentage change in the sum 
of the longest diameters of target marker lesions at 
24 weeks based on this population, but excluding two 
participants who had received cediranib before entering 
the study (an exclusion criterion added after these 
two participants were enrolled).
We report binary endpoints (objective response, best 
response, and clinical benefit) as proportions and 
compared them between treatment groups using Fisher’s 
exact test (one sided). The population analysed for best 
response also included participants who had a scan 
before 24 weeks, but were not evaluable for the primary 
endpoint. For survival-related endpoints, we used the 
ITT population; thus, we still analysed participants 
allocated to placebo who subsequently crossed over as 
belonging to the placebo group. We plotted Kaplan-Meier 
curves for the two treatment groups and compared them 
with the log-rank test. We calculated hazard ratios (HRs) 
and 90% CIs from Cox proportional hazards regression 
models for progression-free survival, with HRs of less 
than 1 favouring cediranib. HRs were not calculated for 
overall survival because of the failure of the proportional 
hazards assumption that is required to use Cox 
regression, as anticipated before the analysis. All analyses 
were unadjusted. Similar to the primary endpoint, we did 
a sensitivity analysis for progression-free survival and 
overall survival, excluding two participants who had 
received cediranib before entering the study. We planned 
two additional sensitivity analyses for progression-free 
survival: one to include participants who had non-
RECIST confirmed progression, and the other was a 
landmark analysis, also including participants who had 
non-RECIST confirmed progressio,n but censoring 
participants 26 weeks after random assignment to 
provide insight into progression-free survival in the 
absence of crossover.
The safety analysis population included all treated 
participants (ie, all those who received at least one dose 
of study drug or placebo), and we summarise the worst 
grades of adverse events during the blinded treatment 
phase. We did no formal comparisons of safety between 
treatment groups because of the small patient numbers. 
We present here any adverse event that was reported in at 
least 10% of participants in either treatment group, or in 
one or more participants for grade 3 and worse events. 
We also report on the number of serious adverse 
reactions to cediranib.
We also did an unplanned, exploratory analysis to 
explore the effect of previous tyrosine-kinase inhibitor 
therapy on progression-free survival.
Post hoc, we analysed duration of response (calculated 
as time from first response, complete or partial response, 
to date of progression), and the proportion of participants 
in each group who had a clinical benefit at 24 weeks for 
completeness and to enable comparison with other 
studies.
Analyses are based on a database snapshot taken on 
April 11, 2018. We did all analyses with Stata (version 13.1). 
This study is registered with ClinicalTrials.gov, number 
NCT 0133740; on the ISRCTN registry, number ISRCTN 
63733470; and on the European Clinical Trials database, 
number EudraCT 2010-021163-33.
Role of the funding sources
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all data in the study and final responsibility for 
the decision to submit for publication.
Results
Between July 15, 2011, and July 29, 2016, 48 patients 
recruited from 12 hospitals in three countries (n=31 from 
seven hospitals in the UK, n=9 from three hospitals in 
Spain, and n=8 from two hospitals in Australia) were 
enrolled. More participants were recruited than were 
originally planned under the recommendation of the 
IDMSC to account for the four participants who were not 
evaluable for the primary endpoint and two participants 
who had received cediranib previously. 32 participants 
were randomly assigned to cediranib and 16 to placebo 
(figure 1) and baseline characteristics were well balanced 
between the treatment groups (table 1). Median age at 
baseline was 31 years (IQR 27–45), with most participants 
in the 20–29 years age group. More than half of 
participants were diagnosed within 2·5 years of trial 
entry, the most common site of disease was the upper leg 
or groin and 11 (23%) of 48 participants had known brain 
metastases at trial entry. 20 (42%) participants had 
previously received tyrosine-kinase inhibitor treatment, 
including two (4%) with previous cediranib.
A planned interim analysis was done of a snapshot of 
data taken on Feb 4, 2014, and did not meet the stopping 
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criteria for the primary endpoint (appendix p 57), thus 
the study continued until the primary analysis. Of 
32 participants randomly assigned to cediranib, one (3%) 
did not start treatment and three (6%) did not have their 
scan at 24 weeks (one of whom discontinued due to 
toxicity). Median time on blinded treatment was 
23·9 weeks (IQR 20·1–24·6) for participants assigned to 
cediranib and 22·2 weeks (IQR 9·6–23·8) for those 
assigned to placebo. Of those who started treatment, 
14 (45%) in the cediranib group and four (25%) in the 
placebo group had at least one dose modification, dose 
delay, or missed dose during blinded treatment because 
of adverse events. 11 (35%) of 31 who were given blinded 
cediranib did not continue to open-label treatment; 
eight (26%) because of disease progression, one (3%) 
because of haematemesis, one (3%) because of 
palmar-plantar erythrodysesthesia and fatigue, and 
one (3%) because of general poor tolerance and planned 
surgery. All participants allocated to placebo went on to 
have at least one dose of open-label cediranib. Of 36 (75%) 
participants who started open-label cediranib, eight (five 
from the cediranib group and three from the placebo 
group) were still on treatment at the data cutoff for this 
analysis. Reasons for discontinuation in the remaining 
28 participants were disease progression (n=21), adverse 
events (n=2), patient choice (n=4), and death (n=1). 
Median time on open-label cediranib was 41·6 weeks 
(IQR 21·0–67·0) for the participants from the cediranib 
group and 40·3 weeks (12·2–108·6) for those from the 
placebo group.
In the evaluable population (44 [92%] of 48 enrolled 
patients), we found a significant difference in the median 
percentage change in the sum of the diameters of target 
marker lesions at 24 weeks of −8·3% (IQR –26·5 to 5·9) 
in the cediranib group compared with 13·4% (1·1 to 21·3) 
in the placebo group (one-sided p=0·0010; figure 2).
Best median percentage change in the sum of the 
diameters of target marker lesions by 24 weeks was 
–15·7% (IQR –26·3 to –2·4) with cediranib and 1·2% 
(–2·4 to 10·9) with placebo (one-sided p<0·0001; 
appendix p 2).
Similar results were obtained in the sensitivity analysis 
in the cediranib-naive population (42 [88%] of 
48 participants): median percentage change in the sum 
of the longest diameters (or shortest if nodal disease) 
of target marker lesions at 24 weeks was –4·4% 
(IQR –26·3 to 6·0) with cediranib versus 14·4% 
(1·1 to 22·6) with placebo (one-sided p=0·0019) and best 
percentage change was –15·0% (IQR –26·3 to –2·4) with 
cediranib versus 1·3% (–2·5 to 11·8) with placebo (one-
sided p=0·00010).
The proportion of participants with an objective 
response, based on best response during the blinded 
treatment phase, was 19%, with six of 31 participants on 
cediranib having a partial response at any timepoint 
during the masked treatment phase. However, at week 24, 
three of these participants no longer met RECIST 
criteria for partial response, and thus the proportion of 
participants with an objective response at week 24 was 
11% (three of 28). No participants in the placebo group 
had a partial response during the blinded treatment 
phase (one-sided p=0·072, cediranib vs placebo). 14 (50%) 
of 28 participants in the cediranib group and seven (44%) 
of 16 in the placebo group had stable disease at 24 weeks; 
thus the proportion of participants with clinical benefit 
at 24 weeks was 61% (17 of 28) for cediranib and 44% 
(seven of 16) for placebo (post-hoc analysis). Of the seven 
participants in the placebo group who were stable at 
24 weeks, three had received no treatment in the 
6 months before randomisation, one had surgery to 
the primary disease site, and another three were on 
another tyrosine-kinase inhibitor until a month before 
randomisation. Of the 14 patients randomly assigned to 
cediranib with stable disease or better at 24 weeks before 
therapy, three had no previous treatment; eight had local 
therapy (surgery or radiotherapy, or both) only to primary 
or metastatic sites, or both; two had local therapy and 
another tyrosine-kinase inhibitor; and one had another 
tyrosine-kinase inhibitor only. Median duration of 
response in the six patients in the cediranib group who 
had a partial response during the blinded treatment 
Figure 1: Trial profile
*Found to have a tumour infiltrating their heart after random assignment. †One patient was subsequently found to 
be ineligible because of unconfirmed progression in the 6 months before trial entry. ‡One patient was subsequently 
found to be ineligible because of unconfirmed progression in the 6 months before trial entry, but was included in 
analyses.
32 randomly assigned to cediranib
1 did not start treatment*
31 started treatment
3 did not undergo scan at 
 24 weeks
 1 due to early 
 discontinuation caused 
 by toxicity
 2 due to other reasons†
28 evaluable for primary analysis
27 in cediranib naive population‡
1 had previous cediranib
16 randomly assigned to placebo
16 started treatment
16 evaluable for primary analysis
15 in cediranib naive population
1 had previous cediranib
48 patients recruited
48 enrolled
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phase was 16·0 months (IQR 15·7–26·0); all six patients 
have subsequently progressed (post hoc). Of the 
32 participants assigned to the cediranib group, two (6%) 
who had stable disease up to week 24 subsequently 
achieved a partial response (one by week 32, the other by 
week 40). Notably, at the time of primary analysis with a 
minimum of 6 months follow-up after random 
assignment to treatment, four (25%) of 16 participants in 
the placebo group had not progressed. Percentage change 
in the sum of the diameters of target marker lesions 
from randomisation to beyond week 24 is shown in the 
appendix (pp 3–4).
At the time of data cutoff for this analysis (median 
follow-up of 34·3 months [IQR 23·7–55·6]), the follow-
up period was dominated by time on open-label 
cediranib and 43 (90%) of 48 participants (29 from the 
cediranib group, 14 from the placebo group) had 
had RECIST-confirmed progression or death before 
progression. We found no evidence of a significant 
difference in progression-free survival between the 
treatment groups (unadjusted HR 0·82, 90% CI 
0·47–1·43; p=0·28; figure 3), although, this analysis 
was probably confounded by the crossover to cediranib. 
12-month progression-free survival was 38·7% (95% CI 
22·0–55·2) for cediranib and 34·4% (12·7–57·5) for 
placebo. In a sensitivity analysis excluding those 
participants with previous cediranib treatment, a 
similar result was achieved (unadjusted HR 0·76, 90% 
CI 0·43–1·35; one sided p=0·21). We expect that with 
extended follow-up, the progression-free survival curves 
will increasingly converge due to the proportional effect 
of crossover to active therapy in those patients who 
were originally allocated to placebo. The first planned 
additional sensitivity analysis included three (6%) of 
48 participants (one in the cediranib group and two in 
the placebo group) who had non-RECIST confirmed 
progression (appendix p 5). This analysis showed no 
evidence of a difference between the two groups 
(HR 0·73, 90% CI 0·43–1·24; one-sided p=0·16). The 
second planned sensitivity analysis, the landmark 
Cediranib group 
(n=32)
Placebo group 
(n=16)
Sex
Male 17 (53%) 8 (50%)
Female 15 (47%) 8 (50%)
Age at baseline, years
Median 30·3 (26·8–44·7) 33·1 (29·3–43·5)
<20 0 1 (6%)
20–29 15 (47%) 5 (31%)
30–39 8 (25%) 4 (25%)
40–49 4 (13%) 5 (31%)
50–59 4 (13%) 0
60–69 0 1 (6%)
≥70 1 (3%) 0
ECOG performance status
0 16 (50%) 9 (56%)
1 16 (50%) 7 (44%)
Time since original ASPS diagnosis, years
≤2·5 18 (56%) 8 (50%)
>2·5–5 4 (13%) 6 (38%)
>5–7·5 2 (6%) 0
>7·5–10 2 (6%) 0
>10 6 (19%) 2 (13%)
Site of primary disease
Upper leg or groin 14 (44%) 7 (44%)
Upper limb 6 (19%) 2 (13%)
Lower leg or foot 3 (9%) 3 (19%)
Trunk 4 (13%) 2 (13%)
Buttock 3 (9%) 0
Pelvis 1 (3%) 2 (13%)
Cranial or facial 1 (3%) 0
Synchronous metastases at trial entry
Yes 5 (16%) 0
No 27 (84%) 16 100%)
Brain metastases at trial entry
Yes 8 (25%) 3 (19%)
No 24 (75%) 13 (81%)
(Table 1 continues in next column)
Cediranib group 
(n=32)
Placebo group 
(n=16)
(Continued from previous column)
Previous treatment for ASPS
Any localised treatment
No 7 (22%) 5 (31%)
Yes 25 (78%) 11 (69%)
Surgery 21 (66%) 11 (69%)
To the primary disease site 19 (59%) 10 (63%)
For metastatic disease 10 (31%) 4 (25%)
Radiotherapy 21 (66%) 7 (44%)
To the primary disease site 12 (38%) 7 (44%)
Any systemic treatment
No 19 (59%) 7 (44%)
Yes 13 (41%) 9 (56%)
Chemotherapy 5 (16%) 4 (25%)
Tyrosine-kinase inhibitor 12 (38%) 8 (50%)
Crizotinib 5 (16%) 5 (31%)
Sunitinib 1 (3%) 2 (13%)
Axitinib 2 (6%) 0
Pazopanib 2 (6%) 0
Cediranib 1 (3%) 0
Cediranib plus dovitinib 0 1 (6%)
Sunitinib plus pazopanib 1 (3%) 0
MET inhibitor (ARQ197) 1 (3%) 0
HDAC inhibitor (PXD101) 0 1 (6%)
Data are n (%) or median (IQR). ASPS=alveolar soft part sarcoma. 
MET=hepatocyte growth factor receptor. HDAC=histone deacetylase.
Table 1: Baseline demographic and clinical characteristics and previous 
treatments received for ASPS prior to trial entry
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analysis, showed a significant improvement in 
progression-free survival for participants allocated to 
the cediranib group (appendix p 6). At the time of 
analysis, 24 (50%) of 48 participants had died (16 in the 
cediranib group and eight in the placebo group). As 
expected, we found no evidence of a difference in 
overall survival between the groups (figure 4). Overall 
survival estimates at 12 months were 90·3% (95% CI 
72·9–96·8) for cediranib and 68·8% (95% CI 
40·5–85·6) for placebo (figure 4). Excluding participants 
with previous cediranib treatment, the log rank p value 
(one sided) was 0·42.
The safety population included 47 (98%) participants 
who had at least one dose of trial treatment. The side-
effect profile was as expected for a VEGFR inhibitor. The 
most common adverse events on blinded treatment were 
diarrhoea, hypertension, fatigue, and nausea (table 2). 
Most grade 3 adverse events on cediranib were hyper-
tension and diarrhoea, which were managed by dose 
reduction (adverse events that resulted in doses reductions 
are not shown separately in table 2). No grade 4 adverse 
events or deaths occurred on cediranib during the masked 
phase. 15 serious adverse reactions were reported in 
12 participants (appendix p 8). Of these serious adverse 
reactions, 12 occurred on open-label cediranib. The most 
common symptoms were dehydration (n=2), vomiting 
(n=2), and proteinuria (n=2). One (2%) of 48 participants 
died because of an intracranial haemorrhage 41 days 
after starting open-label cediranib with no evidence of 
cerebral metastases. This event was considered as 
probably related to treatment. All other deaths were 
unrelated to treatment and due to ASPS.
An unplanned exploratory analysis to determine 
the effect of previous tyrosine-kinase inhibitors on 
Figure 2: Percentage change in sum of target marker lesions from baseline to week 24 (or progression if sooner) in all evaluable participants (n=44)
Each bar represents one patient. Where the number of weeks is given, it indicates the timepoint at which progression occurred for those who did not reach the 
24 week assessment. *Patients who progressed had either progression of non-target lesions or appearance of new lesions despite a less than 20% decrease in the sum 
of target marker lesions. †Patient received cediranib before trial entry.
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Figure 3: Progression-free survival
HR=hazard ratio.
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Cediranib
Median progression-free survival 10·1 months (IQR 5·3–19·0)
Placebo
Median progression-free survival 4·9 months (IQR 1·9–20·0)
Unadjusted HR 0·82 90% Cl (0·47–1·43);
one-sided p=0·28
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progression-free survival was difficult to assess because 
small numbers precluded formal comparisons (appendix 
p 7).
Discussion
CASPS has confirmed the activity of cediranib in 
participants with advanced, metastatic ASPS, with a 
significant difference in the median percentage change 
in sum of the diameters of target marker lesions at 
24 weeks compared with placebo. The primary endpoint 
was chosen to show the degree of tumour shrinkage 
occurring in response to cediranib without being 
confounded by treatment crossover. This endpoint was 
considered a more reliable index of treatment effect than 
progression-free survival in light of known indolent 
progression, spon taneous stabilisation, and spontaneous 
regression in this disease.12 Additionally, this uncon-
ventional endpoint was considered more sensitive than 
progression-free survival and thus required fewer 
participants to show a significant difference between the 
two groups—an important con sideration for a trial in 
such a rare disease. The difference in median 
progression-free survival at the time of the analysis was 
not significant, with absolute values of 10·1 months 
(IQR 5·3–19·0) for cediranib and 4·9 months (1·9–20·0) 
for placebo. Our findings here suggest that cediranib 
stabilises metastatic disease and produces objective 
responses, with 19% of participants given cediranib 
having a partial response in the first 24 weeks. Some 
participants with stable disease and partial response had 
long-lasting disease control, with a median duration of 
response of 16 months (IQR 15·7–26·0).
We recognise that our analyses of secondary endpoints 
such as progression-free survival and overall survival are 
underpowered. However, the rarity and indolence of 
ASPS and the incorporation of crossover within the 
randomised trial dictated the use of an unconventional 
primary endpoint and acceptance that demonstration of 
superiority using more conventional criteria would not 
be possible. Progression-free survival and overall survival 
data are reported to enable comparisons with other 
drugs, none of which have yet been studied in a 
prospective randomised trial (eg, sunitinib, pazopanib, 
axitinib, axitinib plus pembrolizumab, anlotinib). Most 
data on other tyrosine-kinase inhibitors are derived from 
reports on small single-centre studies or larger studies in 
soft-tissue sarcomas of which ASPS comprised only a 
small component. Toxicity was as expected for a drug 
of this class and was generally manageable with dose 
interruptions or reductions, with few participants 
allocated to cediranib withdrawing due to treatment side-
effects. Four participants withdrew subsequently because 
of patient choice, two because of adverse events, and 
one died. One death due to a vascular event was deemed 
probably treatment related because thromboembolic 
events are a known side-effect of VEGF receptor 
inhibitors.
Figure 4: Overall survival
Hazard ratio was not calculated for overall survival due to violation of the non-proportionality assumption.
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Cediranib
Median overall survival 27·8 months (IQR 18·8–63·2)
Placebo
Median overall survival 47·3 months (IQR 7·8–not reached)
Cediranib group (n=31) Placebo group (n=16)
Grade 1–2 Grade 3 Grade 1–2 Grade 3
Diarrhoea 26 (84%) 2 (6%) 6 (38%) 0
Hypertension 20 (65%) 6 (19%) 9 (56%) 0
Fatigue 16 (52%) 1 (3%) 6 (38%) 0
Nausea 12 (39%) 0 3 (19%) 0
Dyspnoea 11 (35%) 0 2 (13%) 1 (6%)
Decreased appetite 9 (29%) 0 6 (38%) 0
Arthralgia 9 (29%) 0 2 (13%) 0
Weight decreased 9 (29%) 0 2 (13%) 0
Headache 9 (29%) 0 4 (25%) 0
Hypothyroidism 9 (29%) 0 1 (6%) 0
Cough 8 (26%) 1 (3%) 6 (38%) 0
Abdominal pain 9 (29%) 0 4 (25%) 0
Pain in extremity 7 (23%) 1 (3%) 6 (38%) 0
Constipation 8 (26%) 0 3 (19%) 0
Mucosal inflammation 6 (19%) 1 (3%) 1 (6%) 0
Palmar-plantar erythrodysaesthesia 7 (23%) 0 0 0
Stomatitis 5 (16%) 0 1 (6%) 0
Back pain 5 (16%) 0 1 (6%) 0
Blood bilirubin increased 4 (13%) 0 1 (6%) 0
Dry skin 4 (13%) 0 0 0
Insomnia 4 (13%) 0 2 (13%) 0
Lymphocyte count decreased 3 (10%) 1 (3%) 1 (6%) 0
Upper respiratory tract infection 4 (13%) 0 1 (6%) 0
Asthenia 3 (10%) 1 (3%) 0 0
Neutrophil count decreased 4 (13%) 0 1 (6%) 0
Vomiting 4 (13%) 0 1 (6%) 0
Rash 4 (13%) 0 1 (6%) 0
Nasopharyngitis 3 (10%) 0 4 (25%) 0
(Table 2 continues on next page)
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The idea that inhibitors of angiogenesis, such as VEGF 
receptor inhibitors like cediranib, might be active against 
ASPS was prompted by the observations of dormancy and 
spontaneous stabilisation, and the belief that some form 
of angiogenic switch might be responsible.18 An additional 
explanation, which is not mutually exclusive, is that this 
behaviour could be due to immune surveillance, for which 
supportive clinical data now exist from the use of 
immunomodulatory drugs (eg, pembrolizumab).16
Evidence of lactate as an energy source in ASPS,6 with 
consequent upregulation of HIF1α and VEGF, might 
partially explain the activity of drugs that inhibit VEGF 
receptors, although other targets could be involved. 
Spontaneous regression could be mediated via the 
immune system. A study of the VEGF receptor inhibitor 
axitinib in combination with pembrolizumab investi-
gating immunomodulation in soft-tissue sarcomas 
(NCT02301039) is ongoing.16 In participants with ASPS, 
the proportion with an objective response was 45·5% 
(95% CI 18·1–75·4) and with a 3-month progression-free 
survival estimate of 90·9% (95% CI 50·8–98·7).
To our knowledge, none of the molecularly targeted 
drugs discussed here have been studied as extensively as 
cediranib in ASPS or have shown superior activity. 
A randomised phase 2 study comparing cediranib 
with sunitinib monotherapy (NCT01391962) is currently 
recruiting participants and has yet to report any results. 
This study does not have a no-treatment group, 
precluding control for spontaneous stabilisation or 
regression or variations in the rate of disease progression 
between the groups.
In CASPS, the proportion of participants who had an 
objective response at week 24 (19%) was lower than that 
reported overall by Kummar and colleagues in a phase 2 
trial of cediranib in metastatic ASPS (35%),11 in which 
participants had a slightly lower median age than in this 
study (27 years vs 31 years), but a similar proportion had 
received antiangiogenic therapy previously (26% vs 33% 
in CASPS). A key difference between the studies is that 
participants were not required to have had disease 
progression in the previous 6 months in Kummar and 
colleagues’ study. Although CASPS was open to 
participants aged 16 years and older (in Kummar and 
colleagues’ study, the threshold was ≥18 years) only one 
patient younger than 20 years was recruited, showing the 
predominance of participating centres only seeing adult 
patients.
Undertaking a randomised trial in such a rare disease, 
which has an incidence of less than one per million 
people per year, was challenging. The decision to 
undertake CASPS as a randomised trial was vindicated 
by the fact that seven (44%) of 16 participants in the 
placebo group had stable disease at 24 weeks, despite all 
participants having documented progressive disease 
before study entry. At the time of primary analysis with a 
minimum of 6 months follow-up after random assign-
ment to treatment, four (25%) participants in the placebo 
group had still not progressed. Considering these data, 
following up participants with ASPS for at least 3 months 
to confirm progressive disease before considering 
systemic therapy seems reasonable. The decision to 
allow crossover to cediranib was made on ethical grounds 
to enable all participants in the study access to the drug 
at some stage. This choice inevitably led to confounding 
in the interpretation of overall survival and long-term 
progression-free survival, as shown by the apparent 
convergence of the progression-free survival curves at 
12 months.
The findings of this study support the concept that 
antiangiogenic therapy is active against advanced ASPS. 
Whether or not the spectrum of receptor tyrosine kinases 
inhibited by cediranib is substantially different from that 
of other drugs that are active in this disease (eg, sunitinib) 
is unclear. Based solely on hypertension incidence as a 
surrogate marker in this and other studies, cediranib 
appears to be a potent VEGF receptor inhibitor. 
Comparative data on relative potency in vitro against 
different receptor tyrosine kinases do not seem helpful 
in predicting toxicity profiles, and hypertension is not a 
reliable efficacy biomarker.19
Given the high incidence of metastatic disease and 
poor long-term prognosis of ASPS, together with the lack 
Cediranib group (n=31) Placebo group (n=16)
Grade 1–2 Grade 3 Grade 1–2 Grade 3
(Continued from previous page)
Chest pain 4 (13%) 1 (3%) 4 (25%) 0
Proteinuria 3 (10%) 0 2 (13%) 0
Dysphonia 3 (10%) 0 2 (13%) 0
γ-glutamyltransferase increased 3 (10%) 0 0 1 (6%)
Oedema peripheral 2 (6%) 0 2 (13%) 0
Epistaxis 2 (6%) 0 2 (13%) 0
Dry mouth 2 (6%) 0 2 (13%) 0
Haemoptysis 2 (6%) 0 2 (13%) 0
Oropharyngeal pain 2 (6%) 0 2 (13%) 0
Blood amylase increased 0 1 (3%) 2 (13%) 0
Pain 1 (3%) 0 2 (13%) 0
Anaemia 1 (3%) 0 3 (19%) 0
Injection site haematoma 0 0 2 (13%) 0
Pruritus 0 0 2 (13%) 0
Monoparesis 0 0 2 (13%) 0
Lower respiratory tract infection 0 0 2 (13%) 0
Blood alkaline phosphatase increased 1 (3%) 1 (3%) 0 0
Alanine aminotransferase increased 1 (3%) 1 (3%) 0 0
Pyrexia 2 (6%) 1 (3%) 1 (6%) 0
Hypophosphataemia 2 (6%) 1 (3%) 0 0
Amenorrhoea 1 (3%) 1 (3%) 0 0
Partial seizures 0 1 (3%) 0 0
Adverse events were graded according to Common Terminology Criteria for Adverse Events version 4. Adverse events 
occuring in at least 10% of patients (or one or more patients for grade 3 or worse events) are reported here. There were 
no grade 4 adverse events or deaths due to these causes.
Table 2: Adverse events reported during the blinded treatment phase
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of efficacy of conventional chemotherapy, the con-
firmation of significant clinical activity with cediranib in 
this disease is an important step towards the goal of long-
term disease control for these young patients. Further 
studies using cediranib in ASPS and other sarcomas, in 
conjunction with other drugs with potential activity in 
the disease, are warranted.
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